A Study of Tumor Neoantigen-specific T Cells in the Treatment of Advanced Solid Tumors
Trial Parameters
Brief Summary
The goal of this clinical trial is to learn if tumor neoantigen-specific T cells can treat patients with advanced solid tumors. The main questions it aims to answer are: Evaluate the safety of intravenous infusion of tumor neoantigen-specific T cells in the treatment of advanced solid tumors such as ovarian cancer, non-small cell lung cancer, and colorectal cancer. To evaluate the effectiveness of intravenous infusion of tumor neoantigen-specific T cells in the treatment of advanced solid tumors such as ovarian cancer, non-small cell lung cancer, and colorectal cancer and to study its immunological properties in patients.
Eligibility Criteria
Inclusion Criteria: 1. Age 18-75 years old; 2. Patients with solid malignant tumors confirmed by histology or cytology such as ovarian cancer, non-small cell lung cancer or colorectal cancer; 3. Cancer patients who have failed previous standard treatments or who have refused subsequent chemotherapy and whose expected survival time exceeds 3 months; 4. ECOG: 0-2 points; 5. Patients of childbearing age need to take appropriate protective measures (contraceptive measures or other birth control methods) before enrollment and during the experiment; 6. Those who can understand this trial and have signed the informed consent form; 7. Able to follow the research protocol and follow-up procedures Exclusion Criteria: 1. Those who have received any form of immunotherapy within the past 3 months; 2. Those who need to use immunosuppressants; 3. Those who have received anti-tumor treatment such as tumor chemotherapy, radiotherapy, and secondary and above surgery within the past month; 4. Those who h